<p>隨着全球市場在利率決策和經濟指標的預期中航行，亞洲股市因其獨特的動態而備受關注。在這些發展中，識別潛在被低估的股票可以為希望利用市場價格與內在價值之間差異的投資者提供有趣的機會。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>西安諾瓦星雲科技（SZSE:301589）</td>
<td>CN¥153.53</td>
<td>CN¥302.13</td>
<td>49.2%</td>
</tr>
<tr>
<td>武漢港迪技術（SZSE:002414）</td>
<td>CN¥12.58</td>
<td>CN¥25.14</td>
<td>50%</td>
</tr>
<tr>
<td>Last One Mile 有限公司（TSE:9252）</td>
<td>¥3490.00</td>
<td>¥6861.35</td>
<td>49.1%</td>
</tr>
<tr>
<td>KIYO Learning 有限公司（TSE:7353）</td>
<td>¥694.00</td>
<td>¥1385.64</td>
<td>49.9%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERING 有限公司（KOSDAQ:A036930）</td>
<td>₩28750.00</td>
<td>₩57013.96</td>
<td>49.6%</td>
</tr>
<tr>
<td>JINS HOLDINGS（TSE:3046）</td>
<td>¥5530.00</td>
<td>¥10925.89</td>
<td>49.4%</td>
</tr>
<tr>
<td>Ibiden 有限公司（TSE:4062）</td>
<td>¥12610.00</td>
<td>¥24483.73</td>
<td>48.5%</td>
</tr>
<tr>
<td>H.U. Group Holdings（TSE:4544）</td>
<td>¥3369.00</td>
<td>¥6592.59</td>
<td>48.9%</td>
</tr>
<tr>
<td>FIT Hon Teng（SEHK:6088）</td>
<td>HK$5.78</td>
<td>HK$11.23</td>
<td>48.5%</td>
</tr>
<tr>
<td>北京北摩高科技摩擦材料有限公司（SZSE:002985）</td>
<td>CN¥28.05</td>
<td>CN¥55.78</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 279 只被低估亞洲股票的完整列表。</p>
<p>我們將查看我們篩選工具中的一些最佳選擇。</p>
<h2>Morimatsu International Holdings（SEHK:2155）</h2>
<p><strong>概述：</strong> Morimatsu International Holdings 有限公司專注於設計、製造、安裝、運營和維護化學反應、生物反應和聚合的核心設備和工藝系統，市值為 106 億港元。</p>
<p><strong>運營：</strong> 公司的收入主要來自綜合壓力設備的銷售，金額為 61.6 億人民幣。</p>
<p><strong>公允價值折扣估計：</strong> 47.3%</p>
<p>Morimatsu International Holdings 的交易價格為 8.51 港元，遠低於其估計的公允價值 16.14 港元，表明其基於現金流的估值極具吸引力。儘管過去一個季度內部人士有減持，但預計其收益在未來三年將以 23% 的年率增長，超過收入增長和香港市場的平均水平。然而，其股本回報率在三年內仍然温和，預計為 16.6%。</p>
<ul>
<li>我們對 Morimatsu International Holdings 的專業增長報告暗示其未來財務前景可能強於近期業績。</li>
<li>通過閲讀我們的健康報告，深入瞭解 Morimatsu International Holdings 的資產負債表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:2155 截至 2025 年 12 月的折現現金流</p>
<h2>浙江喬利製藥有限公司（SZSE:300181）</h2>
<p><strong>概述：</strong> 浙江喬利製藥有限公司專注於中藥產品的研究、生產和營銷，業務覆蓋國內外，市值為 122.7 億人民幣。</p>
<p><strong>運營：</strong> 浙江喬利製藥有限公司通過其在國內外市場的中藥產品研究、生產和營銷產生收入。</p>
<p><strong>公允價值折扣估計：</strong> 45.5%</p>
<p>浙江喬利製藥有限公司的交易價格為 17.7 元，顯著低於其估計的公允價值 32.5 元。儘管 3.39% 的股息收益率未能很好地覆蓋自由現金流，但公司顯示出 22.4% 的強勁收入增長，超過中國市場的平均增長率。最近的財務數據顯示，2025 年前九個月銷售和淨收入均有所增加，儘管非現金收益水平較高，但基本面依然強勁。</p>
<ul>
<li>我們的增長報告表明浙江喬利製藥有限公司可能面臨改善的前景。</li>
<li>通過我們的全面財務健康報告，深入瞭解浙江喬利製藥有限公司的複雜情況。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:300181 截至 2025 年 12 月的折現現金流</p>
<h2>青島百合醫療（SZSE:301015）</h2>
<p><strong>概述：</strong> 青島百合醫療有限公司涉及藥品的研究、開發、生產、批發和零售，業務覆蓋中國、美國、香港和英國，市值為 123.2 億人民幣。</p>
<p><strong>運營：</strong> 公司的收入來源於其在中國、美國、香港和英國等多個地區的藥品研究、開發、生產、批發和零售活動。</p>
<p><strong>公允價值折扣估計：</strong> 14.0%</p>
<p>青島百合醫療的交易價格為 23.44 元，相較於其公允價值估計 27.26 元被低估。儘管 2025 年前九個月銷售和淨收入有所下降，但預計公司在未來三年內的收益將顯著增長，儘管增速低於市場平均水平。它在行業內提供良好的相對價值，並預計未來的股本回報率將達到 27.2%。</p>
<ul>
<li>我們的青島百合醫療增長報告中的分析暗示未來財務表現強勁。</li>
<li>在我們的報告中更詳細地瞭解青島百合醫療的資產負債表健康狀況。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SZSE:301015 截至 2025 年 12 月的折現現金流</p>
<h2>利用機會</h2>
<ul>
<li>點擊這裏解鎖我們基於現金流的 279 只被低估亞洲股票的完整列表。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>使用 Simply Wall St 的免費應用程序簡化您的投資策略，並從全球各地的股票研究中受益。</li>
</ul>
<h2>想探索一些替代方案嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>通過顯示強勁增長潛力的公司來增強您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

諾瓦星雲

港迪技術

<p>亞洲股市因其獨特的動態而受到關注，全球市場正在期待利率決策和經濟指標的發佈。識別被低估的股票為投資者提供了機會。基於現金流的頂級被低估股票包括西安諾瓦星雲科技、武漢港迪技術、Last One Mile Ltd、KIYO Learning Ltd、JUSUNG ENGINEERING Ltd、JINS HOLDINGS、Ibiden Ltd、H.U. Group Holdings、FIT Hon Teng 和北京北摩高科技摩擦材料有限公司。森松國際控股、浙江喬利製藥和青島百合醫療因其顯著的公允價值折扣而受到關注</p>

<p>As global markets navigate the anticipation of interest rate decisions and economic indicators, Asia's stock markets are drawing attention for their unique dynamics. Amidst these developments, identifying stocks that are potentially undervalued can offer intriguing opportunities for investors looking to capitalize on discrepancies between market prices and intrinsic values.</p>
<div class="lb-trans"><p>隨着全球市場在利率決策和經濟指標的預期中航行，亞洲股市因其獨特的動態而備受關注。在這些發展中，識別潛在被低估的股票可以為希望利用市場價格與內在價值之間差異的投資者提供有趣的機會。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an NovaStar Tech (SZSE:301589)</td>
<td>CN¥153.53</td>
<td>CN¥302.13</td>
<td>49.2%</td>
</tr>
<tr>
<td>Wuhan Guide Infrared (SZSE:002414)</td>
<td>CN¥12.58</td>
<td>CN¥25.14</td>
<td>50%</td>
</tr>
<tr>
<td>Last One MileLtd (TSE:9252)</td>
<td>¥3490.00</td>
<td>¥6861.35</td>
<td>49.1%</td>
</tr>
<tr>
<td>KIYO LearningLtd (TSE:7353)</td>
<td>¥694.00</td>
<td>¥1385.64</td>
<td>49.9%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERINGLtd (KOSDAQ:A036930)</td>
<td>₩28750.00</td>
<td>₩57013.96</td>
<td>49.6%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥5530.00</td>
<td>¥10925.89</td>
<td>49.4%</td>
</tr>
<tr>
<td>IbidenLtd (TSE:4062)</td>
<td>¥12610.00</td>
<td>¥24483.73</td>
<td>48.5%</td>
</tr>
<tr>
<td>H.U. Group Holdings (TSE:4544)</td>
<td>¥3369.00</td>
<td>¥6592.59</td>
<td>48.9%</td>
</tr>
<tr>
<td>FIT Hon Teng (SEHK:6088)</td>
<td>HK$5.78</td>
<td>HK$11.23</td>
<td>48.5%</td>
</tr>
<tr>
<td>Beijing Beimo High-tech Frictional MaterialLtd (SZSE:002985)</td>
<td>CN¥28.05</td>
<td>CN¥55.78</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>西安諾瓦星雲科技（SZSE:301589）</td>
<td>CN¥153.53</td>
<td>CN¥302.13</td>
<td>49.2%</td>
</tr>
<tr>
<td>武漢港迪技術（SZSE:002414）</td>
<td>CN¥12.58</td>
<td>CN¥25.14</td>
<td>50%</td>
</tr>
<tr>
<td>Last One Mile 有限公司（TSE:9252）</td>
<td>¥3490.00</td>
<td>¥6861.35</td>
<td>49.1%</td>
</tr>
<tr>
<td>KIYO Learning 有限公司（TSE:7353）</td>
<td>¥694.00</td>
<td>¥1385.64</td>
<td>49.9%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERING 有限公司（KOSDAQ:A036930）</td>
<td>₩28750.00</td>
<td>₩57013.96</td>
<td>49.6%</td>
</tr>
<tr>
<td>JINS HOLDINGS（TSE:3046）</td>
<td>¥5530.00</td>
<td>¥10925.89</td>
<td>49.4%</td>
</tr>
<tr>
<td>Ibiden 有限公司（TSE:4062）</td>
<td>¥12610.00</td>
<td>¥24483.73</td>
<td>48.5%</td>
</tr>
<tr>
<td>H.U. Group Holdings（TSE:4544）</td>
<td>¥3369.00</td>
<td>¥6592.59</td>
<td>48.9%</td>
</tr>
<tr>
<td>FIT Hon Teng（SEHK:6088）</td>
<td>HK$5.78</td>
<td>HK$11.23</td>
<td>48.5%</td>
</tr>
<tr>
<td>北京北摩高科技摩擦材料有限公司（SZSE:002985）</td>
<td>CN¥28.05</td>
<td>CN¥55.78</td>
<td>49.7%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 279 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 279 只被低估亞洲股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看我們篩選工具中的一些最佳選擇。</p>
</div><h2>Morimatsu International Holdings (SEHK:2155)</h2>
<div class="lb-trans"><h2>Morimatsu International Holdings（SEHK:2155）</h2>
</div><p><strong>Overview:</strong> Morimatsu International Holdings Company Limited specializes in designing, manufacturing, installing, operating, and maintaining core equipment and process systems for chemical reactions, biological reactions, and polymerization with a market cap of HK$10.60 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Morimatsu International Holdings 有限公司專注於設計、製造、安裝、運營和維護化學反應、生物反應和聚合的核心設備和工藝系統，市值為 106 億港元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from the sale of comprehensive pressure equipment, amounting to CN¥6.16 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自綜合壓力設備的銷售，金額為 61.6 億人民幣。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 47.3%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 47.3%</p>
</div><p>Morimatsu International Holdings is trading at HK$8.51, significantly below its estimated fair value of HK$16.14, indicating it is highly undervalued based on cash flows. Despite insider selling in the past quarter, its earnings are projected to grow 23% annually over the next three years, outpacing both revenue growth and the Hong Kong market average. However, its return on equity remains modestly forecasted at 16.6% in three years.</p>
<div class="lb-trans"><p>Morimatsu International Holdings 的交易價格為 8.51 港元，遠低於其估計的公允價值 16.14 港元，表明其基於現金流的估值極具吸引力。儘管過去一個季度內部人士有減持，但預計其收益在未來三年將以 23% 的年率增長，超過收入增長和香港市場的平均水平。然而，其股本回報率在三年內仍然温和，預計為 16.6%。</p>
</div><ul>
<li>Our expertly prepared growth report on Morimatsu International Holdings implies its future financial outlook may be stronger than recent results.</li>
<li>Get an in-depth perspective on Morimatsu International Holdings' balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們對 Morimatsu International Holdings 的專業增長報告暗示其未來財務前景可能強於近期業績。</li>
<li>通過閲讀我們的健康報告，深入瞭解 Morimatsu International Holdings 的資產負債表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/743c07aa-1181-4742-99ba-a9c4f184b71b/chart/dcf?theme=light"/></p>
<p>SEHK:2155 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>SEHK:2155 截至 2025 年 12 月的折現現金流</p>
</div><h2>Zhejiang Jolly PharmaceuticalLTD (SZSE:300181)</h2>
<div class="lb-trans"><h2>浙江喬利製藥有限公司（SZSE:300181）</h2>
</div><p><strong>Overview:</strong> Zhejiang Jolly Pharmaceutical Co., LTD focuses on the research, production, and marketing of Chinese medicinal products both domestically and internationally, with a market cap of CN¥12.27 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 浙江喬利製藥有限公司專注於中藥產品的研究、生產和營銷，業務覆蓋國內外，市值為 122.7 億人民幣。</p>
</div><p><strong>Operations:</strong> Zhejiang Jolly Pharmaceutical Co., LTD generates revenue through its research, production, and marketing of Chinese medicinal products in both domestic and international markets.</p>
<div class="lb-trans"><p><strong>運營：</strong> 浙江喬利製藥有限公司通過其在國內外市場的中藥產品研究、生產和營銷產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 45.5%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 45.5%</p>
</div><p>Zhejiang Jolly Pharmaceutical Co., LTD, trading at CN¥17.7, is significantly undervalued with an estimated fair value of CN¥32.5. Despite a dividend yield of 3.39% not well covered by free cash flows, the company shows robust revenue growth at 22.4% annually, outpacing the Chinese market's average growth rate. Recent financials reveal increased sales and net income for the first nine months of 2025, underscoring strong fundamentals despite high non-cash earnings levels.</p>
<div class="lb-trans"><p>浙江喬利製藥有限公司的交易價格為 17.7 元，顯著低於其估計的公允價值 32.5 元。儘管 3.39% 的股息收益率未能很好地覆蓋自由現金流，但公司顯示出 22.4% 的強勁收入增長，超過中國市場的平均增長率。最近的財務數據顯示，2025 年前九個月銷售和淨收入均有所增加，儘管非現金收益水平較高，但基本面依然強勁。</p>
</div><ul>
<li>Our growth report here indicates Zhejiang Jolly PharmaceuticalLTD may be poised for an improving outlook.</li>
<li>Navigate through the intricacies of Zhejiang Jolly PharmaceuticalLTD with our comprehensive financial health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的增長報告表明浙江喬利製藥有限公司可能面臨改善的前景。</li>
<li>通過我們的全面財務健康報告，深入瞭解浙江喬利製藥有限公司的複雜情況。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/622eb9bb-56e4-4333-9ef3-063c670c87d3/chart/dcf?theme=light"/></p>
<p>SZSE:300181 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>SZSE:300181 截至 2025 年 12 月的折現現金流</p>
</div><h2>Qingdao Baheal Medical (SZSE:301015)</h2>
<div class="lb-trans"><h2>青島百合醫療（SZSE:301015）</h2>
</div><p><strong>Overview:</strong> Qingdao Baheal Medical INC. is involved in the research, development, production, wholesale, and retail of pharmaceutical products across China, the United States, Hong Kong, and the United Kingdom with a market cap of CN¥12.32 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 青島百合醫療有限公司涉及藥品的研究、開發、生產、批發和零售，業務覆蓋中國、美國、香港和英國，市值為 123.2 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from its activities in research, development, production, wholesale, and retail of pharmaceutical products across multiple regions including China, the United States, Hong Kong, and the United Kingdom.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入來源於其在中國、美國、香港和英國等多個地區的藥品研究、開發、生產、批發和零售活動。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 14.0%</p>
<div class="lb-trans"><p><strong>公允價值折扣估計：</strong> 14.0%</p>
</div><p>Qingdao Baheal Medical, trading at CN¥23.44, is undervalued compared to its fair value estimate of CN¥27.26. Despite a decline in sales and net income for the first nine months of 2025, the company's earnings are projected to grow significantly over the next three years, though slower than the market average. It offers good relative value within its industry and anticipates high future return on equity at 27.2%.</p>
<div class="lb-trans"><p>青島百合醫療的交易價格為 23.44 元，相較於其公允價值估計 27.26 元被低估。儘管 2025 年前九個月銷售和淨收入有所下降，但預計公司在未來三年內的收益將顯著增長，儘管增速低於市場平均水平。它在行業內提供良好的相對價值，並預計未來的股本回報率將達到 27.2%。</p>
</div><ul>
<li>The analysis detailed in our Qingdao Baheal Medical growth report hints at robust future financial performance.</li>
<li>Take a closer look at Qingdao Baheal Medical's balance sheet health here in our report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的青島百合醫療增長報告中的分析暗示未來財務表現強勁。</li>
<li>在我們的報告中更詳細地瞭解青島百合醫療的資產負債表健康狀況。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/dcf?theme=light"/></p>
<p>SZSE:301015 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>SZSE:301015 截至 2025 年 12 月的折現現金流</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Unlock our comprehensive list of 279 Undervalued Asian Stocks Based On Cash Flows by clicking here.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏解鎖我們基於現金流的 279 只被低估亞洲股票的完整列表。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>使用 Simply Wall St 的免費應用程序簡化您的投資策略，並從全球各地的股票研究中受益。</li>
</ul>
</div><h2>Want To Explore Some Alternatives?</h2>
<div class="lb-trans"><h2>想探索一些替代方案嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>通過顯示強勁增長潛力的公司來增強您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

預計 2025 年 12 月亞洲股票的估值低於其內在價值